Today, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ( Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) . SH) shares fell, closing at 338.32 yuan, down 5.66%.
On July 21, 2021, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) set the highest share price of 491.88 yuan since its listing.
On July 18, 2021, Western Securities Co.Ltd(002673) released the Research Report Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ( Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ): the performance growth exceeded expectations and the experience hall expanded rapidly. The researcher was Wu Tianhao. According to the research report, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) released the forecast of 2021 interim report. During the reporting period, the operating revenue, net profit attributable to parent company and net profit deducted from non parent company were 3.849 billion yuan / 1.114 billion yuan / 1.115 billion yuan respectively, with a year-on-year increase of 18.56% / 28.85% / 29.87% respectively, and the performance growth in the second quarter exceeded the expectation.
The share price of the parent company is expected to be RMB 10.24 billion / year, and the net profit of the parent company is expected to be RMB 10.25 billion / year, respectively, and the purchase price of the parent company is expected to be RMB 2.64 billion / year respectively, with the corresponding rating of “3x 3.06 billion / year”.
Southwest Securities Co.Ltd(600369) researcher Du Xiangyang said in the Research Report “daily chemical industry continues to grow at a high speed and put spin off listing on the agenda” released on July 20, 2021 that the performance of daily chemical industry is bright and the spin off listing is put on the agenda. In 2020, the company adjusted the positioning of daily chemical products from “Trinity” to “Great Health National makeup”. The high-end moisturizing Yurun Xianyan Moisturizing Series was listed in August 2020. So far, the layout of the company’s three high-end skin care product lines has been completed, and the new Three Kingdoms series has entered the stage of mass production. Zhangzhou pianzitan Shanghai Jahwa United Co.Ltd(600315) oral care Co., Ltd., the holding subsidiary of the company, has launched oral care solutions with the core positioning of “clearing fire”. At present, the spin off and listing project has been started, and the project is progressing smoothly. Extensive mergers and acquisitions broaden the product matrix and open up future space for new drug development. In July 2020, the company acquired 51% equity of longhui pharmaceutical and expanded traditional classic Chinese patent medicines such as Angong Niuhuang Pill (shuangnature) and Xihuang Pill (shuangnature). As a traditional and precious traditional Chinese medicine in the field of cardio cerebrovascular, Angong Niuhuang Pill has a market scale of about 2.42 billion yuan. With the brand advantages of Pian Ziguang and the channel advantages of national high net worth crowd experience stores, Pian Ziguang brand Angong Niuhuang Pill is expected to quickly seize the market share. In August 2020, the company’s class 1 new drug pzh2111 was approved for clinical use. The new drug is mainly used to treat advanced solid tumors such as intrahepatic cholangiocarcinoma and urothelial cell carcinoma. On December 2, the company’s class 1 new drug pzh2108 was approved for clinical use. The new drug is mainly used to treat cancer pain. There are no drugs with the same target with the same indications outside China.
It is estimated that the EPS from 2021 to 2023 will be 3.59 yuan, 4.46 yuan and 5.51 yuan respectively, and the corresponding PE will be 121 times, 97 times and 79 times respectively.
